AIM ImmunoTech Inc (GB:0A4Y)
UK Market

AIM ImmunoTech Stock Analysis & Ratings

GB:0A4Y Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$0.95
Average Volume (3M)863.00
Market Cap$37.82M
P/E Ratio-2.4
Next EarningsAug 16, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-0.40



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is AIM ImmunoTech’s market cap?
    AIM ImmunoTech’s market cap is $37.82M.
      What is AIM ImmunoTech’s price target?
      The average price target for AIM ImmunoTech is $3.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 214.80% Increase from the current price of $0.953.
        What do analysts say about AIM ImmunoTech?
        AIM ImmunoTech’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is AIM ImmunoTech’s upcoming earnings report date?
          AIM ImmunoTech’s upcoming earnings report date is Aug 16, 2022 which is in 90 days.
            How were AIM ImmunoTech’s earnings last quarter?
            Currently, no data Available
            Is AIM ImmunoTech overvalued?
            According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
              Does AIM ImmunoTech pay dividends?
              AIM ImmunoTech does not currently pay dividends.
              What is AIM ImmunoTech’s EPS estimate?
              AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does AIM ImmunoTech have?
              AIM ImmunoTech has 39,690,000 shares outstanding.
                What happened to AIM ImmunoTech’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of AIM ImmunoTech?
                Currently, no hedge funds are holding shares in GB:0A4Y


                AIM ImmunoTech Stock Analysis

                The AIM ImmunoTech stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                AIM ImmunoTech Inc

                AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.

                Similar Stocks
                Price & Change
                Merck & Company

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis